GEN Exclusives

More »

GEN News Highlights

More »
Dec 19, 2008

Pfizer Obtains Rights to Novocell’s Pancreatic Progenitor Cells for Diabetes Therapeutics

  • Pfizer has gained access to Novocell’s pancreatic progenitor cells derived from human embryonic stem cells (hESCs) for diabetes research.

    Under terms of this two-year agreement, Novocell will receive payments relating to Pfizer’s sale of any exclusive therapeutic discovered as a result of the collaboration. Pfizer has the option to extend the period of this collaboration.

    Earlier this year, Novocell reports that it demonstrated that hES-derived pancreatic progenitors develop into functioning ductal, acinar, and endocrine cells in vivo. These endocrine cells are capable of producing insulin in response to glucose as well as other pancreatic endocrine hormones in vivo.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Should the CDC Director Resign?

Do you think the CDC chief should resign?